Modulation of Insulin Secretion in Non‐insulin‐dependent Diabetes Mellitus by Two Novel Oral Hypoglycaemic Agents, NN623 and A4166

@article{Kikuchi1996ModulationOI,
  title={Modulation of Insulin Secretion in Non‐insulin‐dependent Diabetes Mellitus by Two Novel Oral Hypoglycaemic Agents, NN623 and A4166},
  author={Masatoshi Kikuchi},
  journal={Diabetic Medicine},
  year={1996},
  volume={13}
}
  • M. Kikuchi
  • Published 1 September 1996
  • Medicine
  • Diabetic Medicine
Two novel oral hypoglycaemic agents, NN623 and A4166, have been developed and are now in phase II clinical trial. Both agents have several common characteristics from sulphonylureas. NN623 is a stereoisomer of derivatives of benzoic acid and A4166 is also a stereoisomer of phenylalanine derivative. The predominant mechanism of the action is thought to be like sulphonylureas. Both NN623 and A4166 occupy, at least partly, a common receptor site with glibenclamide and close the ATP‐dependent K… 
Drug Treatment of Non-Insulin-Dependent Diabetes Mellitus in the 1990s
TLDR
There is intensive pharmaceutical research to find new drugs able to stimulate insulin secretion, improve insulin action, improve carbohydrate absorption or reduce carbohydrate absorption, alone or in combination with currently available drugs.
The mechanisms underlying the unique pharmacodynamics of nateglinide
TLDR
Given that the kinetic profile of the agent is associated with selective enhancement of early-phase insulin secretion, nateglinide is expected to minimise post-meal hyperglycaemia with minimal propensity for hypoglycaemia.
New non-sulfonylurea insulin secretagogues.
  • B. Dunning
  • Medicine
    Expert opinion on investigational drugs
  • 1997
TLDR
Four novel non-sulfonylurea insulin secretagogues are in advanced clinical development and their use in combination with insulin sensitising agents may provide, for the first time, an approximation to ideal metabolic control in NIDDM.
Nateglinide.
  • C. J. Halas
  • Medicine
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 2000
TLDR
Nateglinide, an amino acid derivative of D-phenylalanine, stimulates the secretion of insulin by binding to the ATP potassium channels in pancreatic beta cells, which leads to rapid, short-lived insulin release and is rapidly and completely absorbed in the small intestine.
Pharmacologic restoration of the early insulin response in pre-diabetic monkeys controls mealtime glucose excursions without peripheral hyperinsulinaemia
TLDR
By restoring a more physiologic insulin profile, nateglinide is more effective than repaglinide in controlling prandial glucose excursions with less hyperinsulinaemia.
Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus.
TLDR
Nateglinide (120 mg) was the maximum effective dose in this study and was shown to be a safe and well tolerated therapy for control of mealtime glucose excursions in patients with type 2 diabetes.
No Effect of the Novel Antidiabetic Agent Nateglinide on the Pharmacokinetics and Anticoagulant Properties of Warfarin in Healthy Volunteers
TLDR
There was no evidence of an effect of coadministration of nateglinide on the pharmacodynamic action of warfarin or any pharmacokinetic interaction betweenwarfarin and nategliide.
Clinical Pharmacokinetics of Nateglinide
  • J. McLeod
  • Medicine
    Clinical pharmacokinetics
  • 2004
TLDR
Nateglinide administered prior to meals stimulates rapid, short-lived insulin secretion in a dose-dependent manner, thus decreasing mealtime plasma glucose excursions, and its effects on insulin secretion are synergistic with those of a meal.
Comparison of the postprandial glucose and insulin profiles with nateglinide and gliclazide in type 2 diabetic patients
TLDR
Nateglinide was more effective than gliclazide over an extended postprandial period in type 2 diabetic patients and was associated with earlier, higher and shorter-lived insulin and proinsulin secretory responses.
Toxicology of oral antidiabetic medications.
  • H. Spiller, Tama S Sawyer
  • Medicine
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 2006
TLDR
The toxicity of oral antidiabetic agents differs widely in clinical manifestations, severity, and treatment, and outcomes are routinely good if intervention is initiated early.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 15 REFERENCES
Oral sulfonylurea agents suppress hepatic glucose production in non-insulin-dependent diabetic individuals.
TLDR
The literature concerning the mechanisms of action of the oral sulfonylurea agents on glucose metabolism is reviewed and the results examining the effect of glyburide in 10 non-insulin-dependent diabetic patients are reported.
Different Effects of Glyburide and Glipizide on Insulin Secretion and Hepatic Glucose Production in Normal and NIDDM Subjects
TLDR
The results indicate that the acute administration of GB and GZ to NIDDM subjects has quantitatively different results on hepatic glucose production and acute plasma insulin response to hyperglycemia, challenging the concept that sulfonylurea agents, when given acutely, potentiate glucose-stimulated insulin secretion.
Quantitation of the new hypoglycaemic agent AG-EE 388 ZW in human plasma by automated high-performance liquid chromatography with electrochemical detection.
TLDR
Determination of human plasma samples after intravenous and oral administration of 1 mg of 14C-labelled I demonstrated the applicability of the assay for pharmacokinetic studies in humans.
A new hypoglycaemic agent, A-4166, inhibits ATP-sensitive potassium channels in rat pancreatic ~-cells
  • Am ) Physiol
  • 1995
Early phase II study of a novel oral hypoglycaemic agent, A4166, in Japan
  • Abstracts of 15th /OF Committee,
  • 1994
Early phase II study of a novel oral hypoglycaemic agent, A4166, in Japan. Abstracts of 15th /OF Committee
  • 1994
Novel o-pheylalanine-derivative hypoglycemic agent A-4166 increases cystolic free Ca2+ in rat pancreatic ~-cells by stimulating Ca2+ influx
  • Endocrinology
  • 1994
Suppression by o-phenylaline derivative, A4166, of postprandial hyperglycaemia in dogs
  • Diabetologia
  • 1994
Doseresponse study of a new (non-suphonylurea) agent in diet treated patients with non-insulin dependent diabetes mellitus (NIDDM)
  • Report for Vth World Conference on Clinical Pharmacology and Therapeutics,
  • 1992
Mechanism of action of AG-EE 623 ZW, a novel insulinotropic agent
  • Oiabetologia
  • 1992
...
1
2
...